JPMorgan Chase & Co. Increases Holdings in ARK Genomic Revolution ETF (BATS:ARKG)

JPMorgan Chase & Co. increased its holdings in ARK Genomic Revolution ETF (BATS:ARKG) by 31.0% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 2,955,279 shares of the company’s stock after buying an additional 698,701 shares during the period. JPMorgan Chase & Co. owned 0.05% of ARK Genomic Revolution ETF worth $75,655,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the business. Main Management ETF Advisors LLC increased its holdings in shares of ARK Genomic Revolution ETF by 2.3% during the 2nd quarter. Main Management ETF Advisors LLC now owns 2,754,610 shares of the company’s stock valued at $64,678,000 after purchasing an additional 62,470 shares in the last quarter. Barclays PLC grew its position in shares of ARK Genomic Revolution ETF by 252.7% during the 3rd quarter. Barclays PLC now owns 285,108 shares of the company’s stock valued at $7,299,000 after acquiring an additional 204,283 shares during the period. Northwestern Mutual Wealth Management Co. increased its stake in shares of ARK Genomic Revolution ETF by 2.1% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 166,281 shares of the company’s stock valued at $3,904,000 after purchasing an additional 3,341 shares in the last quarter. Prudential PLC increased its position in shares of ARK Genomic Revolution ETF by 15.0% in the second quarter. Prudential PLC now owns 140,170 shares of the company’s stock valued at $3,326,000 after buying an additional 18,300 shares in the last quarter. Finally, PFM Health Sciences LP acquired a new position in shares of ARK Genomic Revolution ETF during the 3rd quarter worth approximately $2,226,000.

ARK Genomic Revolution ETF Stock Performance

ARK Genomic Revolution ETF stock opened at $25.68 on Friday. The company has a 50-day moving average of $24.67 and a two-hundred day moving average of $24.96.

ARK Genomic Revolution ETF Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.